Florence Eshalomi

Local Housing Allowance (LHA) rates are reviewed annually, usually in the Autumn. LHA determines the maximum housing support for tenants in the private rented sector and do not cover all rents in all areas. The Secretary of State’s decision to maintain LHA rates at current levels for 2025/26 considered a range of factors including rental data; the impacts of LHA rates; the fact that rates were increased in April; and the wider fiscal context.

We currently spend around £32bn annually on housing support for renters. The April 2024 one-year LHA increase cost an additional £1.2bn in 2024/25, and approximately £7bn over 5 years.

For those who need further support, Discretionary Housing Payments (DHPs) are available from local authorities. DHPs can be paid to those entitled to Housing Benefit or Universal Credit who face a shortfall in meeting their housing costs.

We continue to monitor shortfalls and rents and are working with MHCLG on their long-term housing strategy.

We are committed to ensuring that everyone benefits equally from HIV prevention, treatment, and care, and the Department, the UK Health Security Agency (UKHSA), NHS England, and a broad range of system partners are working together to develop a new HIV Action Plan which we aim to publish this year.

We know from the UKHSA’s latest data that women are not benefitting equally from the progress made on HIV as other key groups are, and as part of the new HIV Action Plan we are exploring ways to improve this. The plan will be informed by the UKHSA’s annual data, including the monitoring and evaluation report, which sets out key indicators to track progress towards our 2030 ambitions, including by gender. This data also helps system partners to understand where services can be improved and made more accessible to key populations.

The Department supports research and development, through the National Institute for Health and Care Research (NIHR), which has commissioned research focused on women living with HIV, including the impact of menopause on HIV-positive women's wellbeing and engagement with HIV care, and the intersectional experiences of black women in the digitalisation of sexual and reproductive healthcare, including but not limited to HIV. In addition, the NIHR is funding a £20 million research project to evaluate an expansion of HIV opt-out testing in 47 emergency departments in England where HIV prevalence is high. Emergency department opt-out testing has successfully targeted those who are unlikely to engage with local sexual health services, such as women, and results from the research will be considered in the development of the new plan.

There has also been significant progress through the Department’s national HIV Prevention Programme, which supports communities disproportionately affected by HIV, including women, in particular black African and heterosexual women. The programme delivers National HIV Testing Week, aimed at improving testing and increasing awareness of HIV prevention. During 2024 Testing Week, self-testing was particularly popular amongst women, with a nearly 41% increase in total self-testing orders compared with 2023.

The Department is committed to maximising the United Kingdom’s potential to lead the world in clinical research, with the aim of ensuring that all patients, including those with human immunodeficiency virus (HIV), have access to cutting-edge clinical trials and innovative, lifesaving treatments.

The Department is working closely with the National Health Service, industry, academia, research regulators and charities to make clinical research in the UK more efficient, more competitive and more accessible. We expect these efforts to attract more commercial investment in clinical research and yield a broad and diverse portfolio of clinical trials in the UK, including clinical trials for HIV patients.

The Medicines and Healthcare products Regulatory Agency (MHRA) is ready to assess any market authorisation applications for HIV vaccines against high standards of quality, safety and efficacy. A standard assessment would take up to 210 days to complete.

The MHRA has several routes to support access to innovative medicines for patients with conditions with unmet need. One such route for doing so is the Early Access to Medicines Scheme (EAMS), and the entry for the scheme is a Promising Innovative Medicine (PIM) Designation. If a PIM Designation was awarded, the application would then continue under the EAMS, where it would be assessed for an EAMS Scientific Opinion, which if awarded would need to be renewed annually. Further information is available at the following link:

https://www.gov.uk/guidance/apply-for-the-early-access-to-medicines-scheme-eams

Another route is the Innovative Licensing and Access Pathway (ILAP), which is focused on getting the most transformative new medicines to patients in the UK health system more quickly. The ILAP is the only end-to-end access pathway in the world where the developer can work collaboratively with the national health system, the regulator, and Health Technology Assessment bodies. Further information is available at the following link:

https://www.gov.uk/government/publications/innovative-licensing-and-access-pathway-ilap

The Department funds research through the National Institute of Health and Care Research (NIHR). The NIHR funds clinical research into HIV as well as vaccine development, however, it is not currently funding any trials on HIV vaccines. The NIHR welcomes research proposals on candidates that are ready to be trialled in humans.

The Government is committed to ensuring equality and equity of access to HIV prevention and treatment for all. We recognise that testing is the best way to determine your HIV status, and to ensure people can take appropriate measures to protect themselves and others from transmitting or acquiring HIV.

We are making excellent progress with the blood borne virus opt-out testing programme in the highest HIV prevalence areas, helping us reach those who do not typically engage with sexual health services. In its first 28 months, the programme has identified 1,360 undiagnosed or untreated HIV cases, and over 5,000 cases of untreated or undiagnosed hepatitis B and hepatitis C.

The Department has commissioned officials for advice on how to progress the development of a new HIV Action Plan, including content and scope, which we aim to publish by summer 2025.

The Government is committed to ensuring equality and equity of access to HIV prevention and treatment for all. We have commissioned officials for advice on how to progress the development of a new HIV Action Plan, which we aim to publish by summer 2025. This will include seeking advice from our community and voluntary sector partners on how best to engage and consider the specific needs of under-served and at-risk communities.

HIV Prevention England (HPE) is the national HIV prevention programme for England. It delivers a nationally co-ordinated programme of HIV prevention work for communities at higher risk of transmission such as black African heterosexual communities and gay, bisexual, and other men who have sex with men. HPE is funded by the Department, who have appointed the Terrence Higgins Trust, a national charity who campaign about, and provide services related to, sexual heath and HIV, to deliver the programme from 2021 to 2025.

The programme has recently hosted their 6th biannual conference, which brought together over 200 representatives from the HIV sector to share ideas, best practice, and research, drawing attention to the need to prioritise impactful and equitable interventions, considering the specific needs of those at greater risk. The presentations, workshops and materials will be made available online at HPE’s website next week.

The UK remains committed to sustainable development goal 3.3 including ending AIDS by 2030. The UK supports partners including UNAIDS, Unitaid, and the Global Fund to improve equitable access to HIV prevention services tailored to individual needs. In 2023, the Global Fund partnership reached 17.9 million people with HIV prevention services. Unitaid recently committed $17 million in market-shaping grants to accelerate affordable access to long-acting lenacapavir for HIV prevention. UK investment in research and development supported the development of the dapivirine vaginal ring, another important tool for HIV prevention.

During his visit to DRC in August, the Parliamentary Under-Secretary of State (Africa), Lord Collins, announced £3.1 million UK funding to UNICEF for cholera and mpox response in DRC. It will reach 4.4 million people in affected communities and will boost the DRC's national response for mpox by bolstering surveillance, and ensuring thousands of patients can access healthcare as well as nutritious food to fight infection. The UK is also providing £340 million core voluntary contribution to WHO over 2020-2024, as well as £3 million to WHO's regional office to Africa for health emergency response.